← Back to Clinical Trials
Recruiting NCT07484464

NCT07484464 Effects of the Otago Exercise Program on Balance, Endurance, and Motor Coordination in Children With Down Syndrome

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07484464
Status Recruiting
Phase
Sponsor Riphah International University
Condition Down Syndrome
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2026-03-02
Primary Completion 2026-07-30

Eligibility & Interventions

Sex All sexes
Min Age 8 Years
Max Age 14 Years
Study Type INTERVENTIONAL
Interventions
OTAGO Exercises

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2026-03-02 with a primary completion date of 2026-07-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The study will use a quasi-experimental design conducted over ten months in pediatric physiotherapy departments of tertiary care hospitals and special education schools. It will include 30 children aged 6-14 years with mild to moderate intellectual disability, selected after eligibility screening and guardian consent. Outcomes will be assessed using BOT-2, Berg Balance Scale, MMSE-C, and Six-Minute Walk Test to measure motor skills, balance, cognition, and endurance. Ethical approval will be obtained from the Research Ethical Committee of Riphah International University, Lahore, and data will be analyzed using SPSS version 26.0.

Eligibility Criteria

Inclusion Criteria: * • Clinically diagnosed with Trisomy 21. * Aged between 8-14 years.(29) * Able to follow basic verbal instructions. * Ambulatory with or without assistive devices Exclusion Criteria: * • Severe visual or auditory impairments. * Patient with moderate to severe cognitive impairments. (29) * Co-morbid neurological conditions (e.g., uncontrolled seizures, cerebral palsy). * Cardiac contraindications to moderate physical activity

Contact & Investigator

Central Contact

IMRAN AMJAD, PhD

✉ imran.amjad@riphah.edu.pk

📞 9233224390125

Principal Investigator

FATIMA TARIQ, MS-PT

PRINCIPAL INVESTIGATOR

Riphah International University

Frequently Asked Questions

Who can join the NCT07484464 clinical trial?

This trial is open to participants of all sexes, aged 8 Years or older, up to 14 Years, studying Down Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07484464 currently recruiting?

Yes, NCT07484464 is actively recruiting participants. Contact the research team at imran.amjad@riphah.edu.pk for enrollment information.

Where is the NCT07484464 trial being conducted?

This trial is being conducted at Lahore, Pakistan.

Who is sponsoring the NCT07484464 clinical trial?

NCT07484464 is sponsored by Riphah International University. The principal investigator is FATIMA TARIQ, MS-PT at Riphah International University. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology